Drugs / Fepixnebart
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01545583 | Apr → Sep 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01774981 | Mar 2013 → Aug 2015 | diabetic kidney disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04529096 | Aug 2020 → Jun 2021 | chronic pain syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04476108 | Jul 2020 → Jul 2021 | diabetic polyneuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04456686 | Jul 2020 → Apr 2021 | osteoarthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT05986292 | Jan 2020 → Apr 2027 expected | chronic pain syndrome, diabetic polyneuropathy, osteoarthritis, knee | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fepixnebart | “Fepixnebart (LY3016859), a humanized immunoglobulin G4 monoclonal antibody with high binding affinity to epiregulin and tumor growth factor-α, is being developed as a novel...” PMID 40266472 ↗ Apr 20251“Fepixnebart (LY3016859), a humanized immunoglobulin G4 monoclonal antibody with high binding affinity to epiregulin and tumor growth factor-α, is being developed as a novel...” PMID 40266472 ↗ Apr 2025 |
| Known as | LY3016859 | “Fepixnebart (LY3016859), a humanized immunoglobulin G4 monoclonal antibody with high binding affinity to epiregulin and tumor growth factor-α, is being developed as a novel...” PMID 40266472 ↗ Apr 2025 |
| Action | Inhibit | “Protransforming growth factor alpha inhibitor” CHEMBL4594573 ↗1“Proepiregulin inhibitor” CHEMBL4594573 ↗ |
| Modality | Monoclonal antibody | “a humanized immunoglobulin G4 monoclonal antibody” PMID 40266472 ↗ Apr 2025 |
| Route | Intravenous | “Administered intravenously” NCT01545583 ↗ |
| Target | EREG | “Proepiregulin inhibitor” CHEMBL4594573 ↗ |
| Target | TGFA | “Protransforming growth factor alpha inhibitor” CHEMBL4594573 ↗ |